Treatment considerations for persons with metastatic prostate cancer: Survival versus out-of-pocket costs

Urology

Volumn 49, Issue 2, 1997, Pages 218-224

  Matchar, David B ^a   McCrory, Douglas C ^b   Bennett, Charles L ^b  

^a DUKE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUTAMIDE;

ADULT; ANOREXIA; ARTICLE; BONE PAIN; CANCER SURVIVAL; DRUG COST; HEALTH CARE COST; HEALTH MAINTENANCE ORGANIZATION; HUMAN; MEDICAL DECISION MAKING; MEDICARE; METASTASIS; NORMAL HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; COSTS AND COST ANALYSIS; FLUTAMIDE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PHYSICIAN'S PRACTICE PATTERNS; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0031034148     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00434-7     Document Type: Article

References (11)

1. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, and Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419-424, 1989.
2. Denis LJ, Carnelro de Moura JL, Bono A, Sylvester R, Whelan P, Newling D, and Depauw M. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology 42: 119-130, 1993.
3. Anonymous: Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Overview Group. Lancet 346: 265-269, 1995.
4. Bennett CL, Matchar DB, McCrory D, McLeod DG, Crawford ED, and Hillner BE: Cost-effectiveness models of flutamide for prostate cancer: are they helpful to policy makers? Cancer 77: 1854-1861, 1996.
5. Hillner BE, McLeod DG, Crawford ED, and Bennett CL: Estimating the cost-effectiveness of total androgen blockade with flutamide in Ml prostate cancer. Urology 45: 633-640, 1995.
6. Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, and Kolvenbag G. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with lutenizing hormone-releasing analogue therapy. Urology 47(suppl): 54-60, 1996.
7. Nord E: Methods for quality adjustment of life years. Soc Sci Med 34: 560-566, 1992.
8. Zavoina R, and McElvey W: A statistical model for the analysis of ordinal level dependent variables. J Math Soc 4: 103-120, 1975.
9. Harlan L, Brawley O, Pommerenke F, Wali P, and Kramer B: Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol 13: 93-100, 1995.
10. MacKillop WJ, Ward GK, and O'Sullivan B: The use of expert surrogates to evaluate clinical trials in non-small cell cancer lung cancer. Br J Cancer 54: 661-667, 1986.
11. MacKillop WJ, Palmer MJ, O'Sullivan B, Ward GK, Steele R, and Dostikas G: Clinical trials in cancer: the role of surrogate patients in defining what constitutes an ethically acceptable clinical experiment. Br J Cancer 59: 388-395, 1988.